Stocks · Healthcare · Biotechnology
Caris Life Sciences, Inc. CAI
$30.39 +7.39% Close, Oct 5, 2026 · NASDAQ · Market cap $8.00B
High quality
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $989.6M, up 85.4% from a year earlier, slowing from 100.5% a quarter earlier.
- Operating margin widened to 15.5% from -25.8% a year earlier.
- The stock is in an uptrend: above its 200-day average for 33 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 11%
- Revenue growth, 3-year CAGRTop 15%
- Revenue growth accelerationBottom 14%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 9%
- Gross marginTop 43%
- Operating marginTop 17%
- Cash conversion (OCF / net income)Top 34%
- Accruals (lower is better)Top 43%
- Net debt / EBITDA (lower is better)Top 16%
- Interest coverTop 31%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 26%
- Free-cash-flow yieldTop 30%
- EBITDA / enterprise valueTop 31%
- Sales / enterprise valueBottom 36%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 28%
- 6-month returnTop 17%
- 1-year return vs S&P 500Bottom 45%
- Distance from 52-week highTop 17%
- Trend checklist (0–4)Top 10%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 34%
- Upside to consensus price targetBottom 5%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 24%
- Maximum drawdown, 3 yearsTop 39%
- Beta vs S&P 500 (lower is better)Bottom 9%
- Net debt / EBITDA (lower is better)Top 16%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 100.5% | 85.4% | ↓ |
| Gross margin | 53.5% | 69.7% | ↑ |
| Operating margin | -25.8% | 15.5% | ↑ |
| FCF margin | -26.3% | 14.8% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 85.4% | 100.5% | ↓ | Top 11% |
| Gross margin | 69.7% | 53.5% | ↑ | Top 43% |
| Operating margin | 15.5% | -25.8% | ↑ | Top 17% |
| Net margin | 10.6% | -52.3% | ↑ | — |
| Free-cash-flow margin | 14.8% | -26.3% | ↑ | — |
| Return on invested capital | 14.7% | — | Top 9% | |
| Revenue growth, 3-year CAGR | 46.5% | — | Top 15% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.92×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -7.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 6.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +44.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -1.38×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 3.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.39%
- Shareholder yield
- 0.39%
- Share count change, 1 year
- +2.5%
- Share count change, 3-year CAGR
- +152.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 6
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +2.4%
- Positive 20 days after report
- 3 of 5
Analysts
- Consensus price target
- $26.00
- Target vs current price
- -14.4%
- Analysts with a rating
- 7
- Share rating Buy or Strong Buy
- 86%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -139.2% | +2.2% | +43.7% | +53.9% | — |
| May 7, 2026 | +91.0% | +3.7% | -23.2% | -9.7% | -14.7% |
| Feb 26, 2026 | +2700.0% | +5.1% | +8.5% | +1.4% | -12.9% |
| Nov 5, 2025 | +200.0% | -6.3% | -19.3% | -12.6% | -25.2% |
| Aug 12, 2025 | -157.1% | +7.4% | +19.0% | +12.4% | +3.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.00 | $0.01 | -139.2% | $263.7M |
| May 7, 2026 | -$0.00 | -$0.02 | +91.0% | $216.2M |
| Feb 26, 2026 | $0.28 | $0.01 | +2700.0% | $292.9M |
| Nov 5, 2025 | $0.08 | -$0.08 | +200.0% | $216.8M |
| Aug 12, 2025 | -$0.54 | -$0.21 | -157.1% | $181.4M |
| Jun 9, 2025 | -$0.35 | -$0.22 | -60.3% | $120.9M |
| Nov 5, 2021 | $2.95 | $0.61 | +383.6% | $100.8M |
| Aug 3, 2021 | $2.20 | $1.20 | +83.3% | $85.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 84.9× | — | — | Top 26% |
| P/E (forward) | 254.6× | — | — | — |
| EV / EBITDA | 44.9× | — | — | Top 31% |
| EV / Sales | 7.84× | — | — | Bottom 36% |
| Free-cash-flow yield | 1.83% | — | — | Top 30% |
| Earnings yield | 1.18% | — | — | Top 26% |
P/E over the past five years
Range 3.6× – 46.0× since Mar 31, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 42
- Days above the 200-day average
- 33
- 50-day average slope (20 days)
- +23.9%
- 200-day average slope (20 days)
- +1.3%
- Distance from 50-day average
- +22.8%
- Distance from 200-day average
- +43.2%
- RSI (14)
- 59.8
- Relative volume
- 1.00×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 74.2%
- Volatility vs own 5-year history
- 76th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.20
- Correlation with S&P 500
- 0.36
- Current drawdown from 1-year high
- -7.8%
- Maximum drawdown, 3 years
- -63.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Aug 22, 2025 | May 15, 2026 | -63.0% | 183 days | Not yet recovered |
| Jul 16, 2025 | Jul 28, 2025 | -13.8% | 8 days | 11 days (Aug 12, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $8.00B
- P/E (TTM)
- 84.9
- EPS, diluted (TTM)
- $0.36
- Revenue (TTM)
- $989.6M
- 52-week range
- $14.19 – $33.65
| FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $294.0M | $258.5M | $306.1M | $412.3M | $812.0M |
| Gross profit | $184.2M | $80.0M | $89.3M | $178.8M | $539.2M |
| Operating income | $139.1M | -$315.8M | -$319.6M | -$257.1M | $45.1M |
| Net income | $27.7M | -$320.8M | -$341.4M | -$281.9M | -$538.0M |
| EPS (diluted) | $1.55 | -$1.57 | -$1.82 | -$2.70 | -$1.86 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $101.6M | $129.9M | $120.9M | $181.4M | $216.8M | $292.9M | $216.2M | $263.7M |
| Net income | -$67.7M | -$36.9M | -$102.6M | -$71.8M | $24.3M | $82.0M | -$510,000 | -$637,000 |
| EPS (diluted) | -$0.33 | -$0.22 | -$0.40 | -$1.87 | $0.08 | $0.28 | -$0.00 | -$0.00 |
| FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $277.0M | -$285.7M | -$276.1M | -$245.2M | $83.2M |
| Capital expenditure | -$219.4M | -$42.3M | -$22.3M | -$8.4M | -$16.3M |
| Free cash flow | $57.6M | -$328.0M | -$298.4M | -$253.6M | $66.9M |
| Dividends paid | -$17.7M | $0 | $0 | $0 | $0 |
| Net share buybacks | -$7.8M | $0 | $0 | $0 | $667.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $793.1M
- Total assets
- $1.23B
- Total liabilities
- $637.9M
- Total debt
- $452.4M
- Net debt
- -$238.5M
- Shareholders’ equity
- $591.7M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 13,331,431
- Days to cover
- 3.01
- Change vs previous report
- -2.6%
FINRA short interest, settlement date Sep 15, 2026.